Huons' 'Eluvi Menolacto Probiotics' Obtains US Patent for Key Ingredient

Huons 'Eluvi Menolacto Probiotics' (Photo by Huons)

[Asia Economy Reporter Lee Chun-hee] Huons' female menopause probiotic 'Menolacto YT1' has been recognized for its raw material value in the United States.

Huons announced on the 27th that 'Lactobacillus acidophilus YT1 (Menolacto YT1)', the core ingredient of the dual-functional health supplement for female menopause and gut health, 'Eluvi Menolacto Probiotics', has obtained a foundational technology patent from the United States Patent and Trademark Office.

With this patent acquisition, the patent countries for compositions including Menolacto YT1 for the prevention or treatment of female menopause have expanded following Japan in 2020 and Korea last year. The Korea Food Research Institute, a joint research institution for Menolacto YT1, holds the patent, and Huons will exercise exclusive licensing rights.

Thus, Huons has secured composition patents for Menolacto YT1 in Korea, the United States, and Japan. In particular, by obtaining the patent for Menolacto YT1 in the advanced U.S. market, the technology value has been recognized while securing exclusive rights.

Menolacto YT1 was the first in Korea to receive individual recognition as a health functional food with the function of 'helping the health of menopausal women' from the Ministry of Food and Drug Safety in 2019. Since then, the female menopause health functional food Eluvi Menolacto Probiotics, launched in 2020 with this as the core ingredient, recorded sales of 17 billion KRW as a single item that year, and last year recorded cumulative sales of 27.7 billion KRW by the third quarter, solidifying its position as a leading brand for female menopause health functional foods.

A Huons official said, “This U.S. patent is significant in that the probiotic developed with our technology has been globally recognized for its functionality, raw material, and technological value, and has secured exclusive rights.” He added, “Using this as a stepping stone, we will promote the value of Menolacto YT1 and Eluvi Menolacto Probiotics beyond Korea to the world.”